This morning’s announcement that Watkin Jones Plc (LON:WJG) has forward sold the student accommodation element of a development in Bournemouth takes to six the number of developments since the end
We anticipate a robust set of full year results from Pendragon Plc (LON:PDG) next week, with the shares +13% in January following a poor performance in 2016 (-33% in absolute
Epwin Group PLC (LON:EPWN) year-end trading update states that results are in line with expectations which we take to be in line with consensus PBT forecasts of £24.4m, marginally above
Allergy Therapeutics Plc (LON:AGY) is a UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies. This
Zeus Capital’s Dr Tom McColm discusses Ceres Power Holdings plc in this exclusive interview with DirectorsTalk
Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), a late clinical stage antibiotic development company, has announced that the treatment phase has finished for the last patient in REVIVE-1, the first of two
We flag this morning’s announcement and note that the amendment to the interim EPS calculation as announced yesterday in the accounts does not affect our forecasts which remain unchanged. We
Mi-Pay Group plc (LON:MPAY) has released an encouraging trading statement this morning confirming FY16 revenue will be in line with ZC estimates at £3.3m (FY15: £3.0m). The yoy growth of
Ceres Power Holdings plc (LON:CWR) CEO Phil Caldwell chats with DirectorsTalk about it’s latest trading update. Phil talks about the last 6 months, opportunities for the company, the effects of
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
